The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial. — CFSMEATLAS
The effects of 3-month supplementation with synbiotic on patient-reported outcomes, exercise tolerance, and brain and muscle metabolism in adult patients with post-COVID-19 chronic fatigue syndrome (STOP-FATIGUE): a randomized Placebo-controlled clinical trial.
Ranisavljev, Marijana, Stajer, Valdemar, Todorovic, Nikola et al. · European journal of nutrition · 2024 · DOI
Quick Summary
This study tested whether a special mixture of beneficial gut bacteria (probiotics) plus fiber and zinc could help people with post-COVID chronic fatigue syndrome (ME/CFS). Over three months, 26 patients took either the synbiotic mixture or a placebo, and researchers measured their fatigue, exercise recovery, and brain/muscle chemistry. The synbiotic group experienced better recovery after exercise and showed improvements in brain chemistry compared to the placebo group, though both groups felt less general fatigue.
Why It Matters
Post-COVID ME/CFS affects millions globally with limited treatment options, and gut microbiota dysfunction is an increasingly recognized feature of the condition. This study provides preliminary evidence that targeted microbial supplementation may address both gastrointestinal issues and core ME/CFS symptoms like post-exercise malaise, offering a potentially safe and accessible intervention worthy of larger investigation.
Observed Findings
Both synbiotic and placebo groups experienced significant reductions in general fatigue after 3 months compared to baseline
Synbiotic treatment showed significantly greater reduction in post-exercise malaise compared to placebo (P=0.02)
Synbiotic group demonstrated increased choline levels in the thalamus compared to placebo (P=0.02)
Synbiotic group showed higher creatine levels in left frontal white matter (P=0.05) and left frontal grey matter (P=0.04) versus placebo
Inferred Conclusions
Three-month synbiotic supplementation improves tissue metabolism in the brain and mitigates post-exercise malaise in post-COVID ME/CFS patients
The synbiotic mixture may offer a safe, cost-effective nutritional strategy for addressing ME/CFS given observed gastrointestinal involvement in the condition
Further validation studies are needed before recommending synbiotics as a standard clinical intervention for post-COVID fatigue syndrome
Remaining Questions
Which specific components (bacterial strains vs. prebiotics vs. zinc) drive the observed benefits, and are all necessary?
Do the improvements in brain metabolites (choline, creatine) directly correlate with clinical symptom improvement and functional capacity?
What This Study Does Not Prove
This study does not prove that synbiotics are an effective treatment for ME/CFS—the small sample size (26 patients) and short duration limit confidence in the findings. It also cannot establish which specific bacterial strains or components drive any benefits, nor does it determine whether improvements would persist beyond 3 months or scale to diverse patient populations. The mechanisms linking improved brain metabolism to clinical symptom reduction remain unclear.
What is the optimal duration, dosage, and composition of synbiotic treatment, and do benefits persist beyond 3 months or require ongoing supplementation?
Will results replicate in larger, more diverse post-COVID ME/CFS populations, and does synbiotic efficacy differ in non-COVID ME/CFS patients?